Participated · Equity · Jan 2026

Founded in 2022 in Gironde by veterinarian Romain Delcombel, BioAz is a young animal-health biotech focused on replacing the controversial practice of piglet castration with an immunotherapy approach. Its lead solution aims to neutralize boar taint through a vaccine-like treatment, eliminating the need for surgical intervention and improving animal welfare. The company positions itself at the crossroads of animal health and sustainable livestock production, targeting pork producers and integrators that face increasing regulatory and consumer pressure. BioAz plans to use newly raised capital to accelerate R&D, deepen scientific collaborations, and scale industrial deployment of its first products. While still in early development, the startup has garnered interest from industry-specific investors, underscoring market demand for welfare-friendly animal health innovations. To date, BioAz has secured €900 000 in external funding; no revenue or user metrics have been disclosed.

Led · Seed · Sep 2022

Dalan Animal Health is a bioscience company that created the world’s first USDA-approved vaccine for honeybees and is now advancing what it says will be the first commercial shrimp vaccine. Built on its proprietary Innate Immunity Platform, the firm targets conserved pattern-recognition receptors shared across animal species to deliver broad-spectrum disease protection. After launching its honeybee vaccine, the company is focusing on regulatory approval, manufacturing scale-up, and commercial rollout of its shrimp vaccine to help mitigate the estimated $4 billion in annual shrimp industry losses from disease. Concurrently, Dalan is investigating platform extensions into poultry and additional aquaculture species to reduce antibiotic dependence in food production. The business operates globally, including a European subsidiary, Dalan Bio SL, which recently secured a €250 K grant to conduct pan-European surveillance of honeybee diseases. Recognition for its technology includes TIME’s Best Inventions, Fast Company’s Next Big Things in Tech, and SVG THRIVE Global Impact Challenge winner (2025). The latest financing leaves the company capitalized to complete shrimp vaccine commercialization and expand its product pipeline, though no revenue or user metrics were disclosed.